Trial Profile
A double-blind, randomized, multicenter, parallel group study to establish dose-response, safety, and efficacy of Zonegran (zonisamide) as monotherapy in patients with newly diagnosed epilepsy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2005
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Complex partial epilepsy
- Focus Registrational; Therapeutic Use
- 12 Oct 2005 New trial record.